Diagnostic accuracy of 18F-FDG PET in residual or recurrent differentiated thyroid carcinoma with high thyroglobulin and negative whole-body scan;Eficacia diagnóstica de la PET 18F-FDG en el cáncer diferenciado de tiroides residual o recurrente con tiroglobulina elevada y rastreo con 131-I negativo

Revista Espanola de Medicina Nuclear

Volumn 26, Issue 5, 2007, Pages 263-269

  Cabrera Martin M N ^a   Pasamontes Pingarron J A ^b   Carreras Delgado, J L ^c   Lapena Gutierrez L ^c   Delgado Bolton, R C ^a   Bittini Copano, A ^d   Perez Castejon M J ^a   Fernandez Perez Y C ^c  

^a Instituto PET Focuscan   (Spain)

^b HOSPITAL DE MÓSTOLES   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Differentiated thyroid cancer; FDG PET; Recurrence; Thyroglobulin

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; THYROGLOBULIN;

ARTICLE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; POSITRON EMISSION TOMOGRAPHY; RADIODIAGNOSIS; THYROID CARCINOMA; THYROIDECTOMY; WHOLE BODY SCINTISCANNING;

EID: 35348819429     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1157/13109140     Document Type: Article

References (27)

1. Giammarile F, Hafdi Z, Bournaud C, Janier M, Houzard C, Desuzinges C, et al. Is (18F)-2-fluoro-2-deoxy-D-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake? Eur J Endocrinol. 2003;149:293-300.
2. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W, et al. European consensus for the management of patients with differenciated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787-803.
3. Wu HS, Huang WS, Liu YC, Yen RF, Shen YY, Kao CH. Comparison of FDG-PET and technetium-99m MIBI SPECT to detect metastatic cervical lymph nodes in well-differentiated thyroid carcinoma with elevated serum HTG but negative I-131 whole body scan. Anticancer Res. 2003;23:4235-8.
4. 131I whole-body scan. J Nucl Med. 1999;40:986-92.
5. 18F) fluorodeoxyglucose positron emission tomography in patients with radioiodinenegative recurrent Well-Differenciated Thyroid Carcinoma. Ann Surg. 2001;234:804-11.
6. 131I. Rev Clin Esp. 1998; 198:307-15.
7. Muros MA, Llamas-Elvira JM, Ramírez-Navarro A, Gómez MJ, Rodríguez-Fernández A, Muros T, et al. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differenciated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. Am J Surg. 2000;179:457-61.
8. Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med. 1987;28:910-4.
9. 131I ccanning results after therapy. J Nucl Med. 2001;42: 1464-9.
10. 131I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab. 1999;84:2291-302.
11. 131I-negative papillary thyroid carcinoma. J Nucl Med. 2000;41:1010-5.
12. 18fluor-2-deoxyglucose positron emission tomography in the follow-up of Hürthle cell thyroid cancer. Thyroid. 2002;12:155-61.
13. Conti PS, Durski JM, Bacqai F, Grafton ST, Singer PA. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid. 1999;9:797-804.
14. Grünwald F, Kälicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med. 1999;26:1547-52.
15. 18F)fluorodeoxyglucose positron emission tomography. Nucl Med Commun. 1998; 19:547-54.
16. Stokkel MPM, Klerk JHM, Zelissen PMJ, Koppeschaar HPF, van Rijk PP. Fluorine-18 fluorodeoxyglucose dual-head positron emission tomography in the detection of recurrent differenciated thyroid cancer: preliminary results. Eur J Nucl Med. 1999;26:1606-9.
17. 18F-FDG in thyroid cancer patients with negative 131I whole-body scans. Eur J Nucl Med Mol Imaging. 2004;31: 330-41.
18. 131I. Nuklearmedizin. 1995;34:127-34.
19. Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med. 1996;37:1468-72.
20. Feine U. Fluor-18-deoxyglucose positron emission tomography in differentiated thyroid cancer. Eur J Endocrinol. 1998;138: 492-6.
21. Ruiz Franco-Baux JV, Borrego Dorado I, Gómez Camarero P, Rodríguez Rodríguez JR, Vázquez Albertino RJ, Navarro González E, et al. F-18-fluordeoxyglucose positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan. Rev Esp Med Nucl. 2005;24:5-13.
22. Schelbert HR, Hoh CK, Royal HD, Brown M, Dahlbom MN, Dehdashti F, et al. Procedure guideline for tumor imaging fluorine-18-FDG. J Nucl Med. 1998;39:1302-5.
23. Haberkorn U, Strauss LG, Dimitrakopoulou A, Engenhart R, Oberdorfer F, Ostertag H, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorrectal tumors receiving radiotherapy. J Nucl Med. 1991;32:1485-90.
24. Carreras Delgado JL. Medicina Nuclear basada en la evidencia y Medicina Nuclear basada en la experiencia. Anales de la Real Academia de la Medicina. 2000. Tomo CXVII, cuaderno III:625-54.
25. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med. 1993;12:1293-316.
26. 18F) fluorodeoxyglucose uptake by differenciated thyroid carcinoma. Eur J Nucl Med. 2002;29:641-7.
27. Chin BB, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differenciated thyroid carcinoma. J Clin Endocrinol Metab. 2004;89:91-5.